330 related articles for article (PubMed ID: 27081803)
1. [Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
Richter I; Dvořák J; Hejzlarová V; Chalupa J; Sochor M; Stankuš I; Barsová L; Holikova M; Forster J; Bartoš J
Klin Onkol; 2016; 29(2):127-32. PubMed ID: 27081803
[TBL] [Abstract][Full Text] [Related]
2. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ
Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
[TBL] [Abstract][Full Text] [Related]
5. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
6. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Davies RS; Smith C; Lester JF
Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
[TBL] [Abstract][Full Text] [Related]
7. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
Cheng HH; Gulati R; Azad A; Nadal R; Twardowski P; Vaishampayan UN; Agarwal N; Heath EI; Pal SK; Rehman HT; Leiter A; Batten JA; Montgomery RB; Galsky MD; Antonarakis ES; Chi KN; Yu EY
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):122-7. PubMed ID: 25600186
[TBL] [Abstract][Full Text] [Related]
8. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
Plouznikoff N; Artigas C; Sideris S; Martinez Chanza N; Gil T; Peltier A; Flamen P
Ann Nucl Med; 2019 Dec; 33(12):945-954. PubMed ID: 31587172
[TBL] [Abstract][Full Text] [Related]
11. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
12. Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study.
Maughan BL; Luber B; Nadal R; Antonarakis ES
Prostate; 2017 Jan; 77(1):33-40. PubMed ID: 27527643
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.
Yamada Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S
BMC Res Notes; 2016 Oct; 9(1):471. PubMed ID: 27756383
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P; De Giorgi U; Scarpi E; Fantini L; Moretti A; Galassi R; Celli M; Conteduca V; Rossi L; Bianchi E; Paganelli G; Matteucci F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):348-354. PubMed ID: 29110067
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
Schmid SC; Geith A; Böker A; Tauber R; Seitz AK; Kuczyk M; von Klot C; Gschwend JE; Merseburger AS; Retz M
Adv Ther; 2014 Feb; 31(2):234-41. PubMed ID: 24442834
[TBL] [Abstract][Full Text] [Related]
17. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
Pilon D; Queener M; Lefebvre P; Ellis LA
J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
[TBL] [Abstract][Full Text] [Related]
20. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
Terada N; Maughan BL; Akamatsu S; Kobayashi T; Yamasaki T; Inoue T; Kamba T; Ogawa O; Antonarakis ES
Int J Urol; 2017 Jun; 24(6):441-448. PubMed ID: 28455853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]